MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Long-Term Debt 2011-2026 | NDRA
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 366 K | 547 K | 337 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 547 K | 337 K | 417 K |
Quarterly Long-Term Debt ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 397 K | 429 K | 461 K | 487 K | - | 98.4 K | - | 192 K | 237 K | 281 K | 324 K | 366 K | 434 K | 473 K | 510 K | 547 K | 553 K | 586 K | 252 K | 272 K | 290 K | 272 K | 272 K | 343 K | 343 K | 343 K | 343 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 586 K | 98.4 K | 364 K |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
100 K | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
53.8 M | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
2.15 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
6.4 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
360 K | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
13.9 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
3.48 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
1.18 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
375 M | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
2.73 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
554 M | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.4 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
30.7 M | $ 7.5 | -6.13 % | $ 29.9 M |  Israel |
 |
Guardant Health
GH
|
1.5 B | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.34 B | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
19.7 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
569 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
105 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
114 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
2.09 B | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
120 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
NeoGenomics
NEO
|
342 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
75 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
282 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
3 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Pacific Biosciences of California
PACB
|
56.6 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
1.06 B | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |